Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 108 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 350 |
| 2 | EXPERIMENTAL | 350 |
| 3 | EXPERIMENTAL | 196 subjects |
| 4 | PLACEBO_COMPARATOR | 196 subjects |
| Name | Type | Description |
|---|---|---|
| AMG 108 | DRUG | 125 mg via SC (subcutaneous) injection every 4 weeks |
| Placebo | DRUG | Placebo via SC (subcutaneous) injection every 4 weeks |
Inclusion Criteria: * Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll. Exclusion Criteria: * Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.
Top 20 of 28 competitors
AMG 108 is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is currently in Phase 2 clinical development and has been studied in clinical trials for this condition.
AMG 108 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN.
AMG 108 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 clinical trials for rheumatoid arthritis have been completed.
AMG 108 has been studied in two completed Phase 2 clinical trials for rheumatoid arthritis. These are NCT00293826, which enrolled 813 participants, and NCT00369473, which enrolled 690 participants. Both trials were randomized, double-blind, and controlled.
AMG 108 is the primary name used for this investigational drug. No alternative names have been reported for this compound.